Drug Search Results
Using advanced filters...
Advanced Search [+]

LZ-001

Alternative Names: LZ-001, LZ 001, LZ001
Latest Update: 2025-02-20
Latest Update Note: News Article

Product Description

Livzon Pharma is developing LZ001 tablets, a small molecule ROS1/NTRK/ALK multi-kinase Inhibitor.

Mechanisms of Action: ROS1 Inhibitor,ALK Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Livzon Pharmaceutical Group Co., Ltd.
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for LZ-001

Countries in Clinic: China

Active Clinical Trial Count: 1

Highest Development Phases

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CTR20221852

P1

Not yet recruiting

Oncology Solid Tumor Unspecified

None

Recent News Events